Welcome to CSNpharm! For Research Use Only!
BTK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN22147 | Zanubrutinib | 1691249-45-2 | Zanubrutinib is a selective Bruton tyrosine kinase BTK inhibitor |
| CSN22532 | Vecabrutinib | 1510829-06-7 | Vecabrutinib is a potent BTK inhibitor with IC50s of 46 nM and 11 nM for WT BTK and C481S BTK respectively and also inhibits ITK activity IC50 24 nM |
| CSN28458 | SJF620 | 2376187-16-3 | SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN. |
| CSN15892 | RN486 | 1242156-23-5 | RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM. |
| CSN32900 | Rilzabrutinib | 1575591-66-0 | Rilzabrutinib is a BTK inhibitor. |
| CSN50327 | Remibrutinib | 1787294-07-8 | Remibrutinib is an effective and highly selective inhibitor of Bruton tyrosine kinase (Btk). |
| CSN13816 | QL47 | 1469988-75-7 | QL47 is a potent selective and irreversible BTK kinase inhibitor with IC50 of 7 nM |
| CSN20296 | Poseltinib | 1353552-97-2 | Poseltinib irreversibly bound to and inhibited Btk IC50 value of 1.95nM. It inhibited the phosphorylation of Btk and its downstream molecules such as PLCγ2, in activated Ramos B lymphoma cells and primary human B cells in a dose-dependent manner. |
| CSN28522 | BTK PROTAC 9 | 2250382-64-8 | PON82648, also known as BTK PROTAC 9, is a PROTAC for BTK. |
| CSN20637 | Pls-123 | 1431727-04-6 | PLS-123 is a covalent irreversible Btk inhibitor with potential anti-proliferative activity |
| CSN32454 | Pirtobrutinib | 2101700-15-4 | Pirtobrutinib is a highly selective and non-covalent BTK inhibitor, which may be regarded as a third generation BTK inhibitor. It potently inhibited the cellular activity (measured by Y223 autophosphorylation) of BTK C481S, T and R mutations and displayed strong equilibrium binding to WT BTK and several BTK C481 substitution mutations. It may overcome acquired resistance to covalent BTK inhibitors in patients without significant off-target toxicity. |
| CSN24174 | PF-06250112 | 1609465-89-5 | PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5nM, 0.9nM and 1.2nM for BTK, BMX Kinase and TEC, respectively. |
| CSN18605 | Ibrutinib Racemate | 936563-87-0 | PCI-32765 racemate is a potent and highly selective Btk inhibitor with IC50 of 05 nM modestly potent to Bmx CSK FGR BRK HCK less potent to EGFR Yes ErbB2 JAK3 etc |
| CSN18219 | PCI 29732 | 330786-25-9 | PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay. |
| CSN28511 | P13I | 2360561-66-4 | P13I is a novel PROTAC BTK degrader, efficiently degrading ibrutinib-sensitive BTK-WT (wild type), significantly inducing the degradation of ibrutinib-resistant BTK-C481S. |
| CSN27283 | Orelabrutinib | 1655504-04-3 | Orelabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
| CSN17862 | Tirabrutinib hydrochloride | 1439901-97-9 | ONO-4059 is a selective inhibitor of BTK with IC50 22 nm ONO-4059 binds to BTK within B cells thereby preventing B-cell receptor signaling and impeding B-cell development |
| CSN17733 | Tirabrutinib | 1351636-18-4 | ONO-4059 is a highly selective and orally bioavailable BTK inhibitor with a IC50 of 2.2 nM. |
| CSN17732 | ONO-4059 analog | 1351635-67-0 | ONO-4059 Analog is a highly selective BTK inhibitor with IC50 of 22 nM |
| CSN22302 | MT-802 | 2231744-29-7 | MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM); MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome; MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK, elicits complete BTK knockdown at 250 nM; reduces the pool of active, phosphorylated BTK in cells isolated from CLL patients with the C481S mutation, whereas ibrutinib cannot. |
| CSN21709 | 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide | 62004-35-7 | LFM-A13 is specific inhibitor of bruton’s tyrosine kinase (BTK) with IC50 of 17.2 µM and 2.5 µM for recombinant BTK. |
| CSN19154 | Ibrutinib-biotin | 1599432-18-4 | Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker with an IC50 of 0755-102 nM for BTK |
| CSN19159 | Fenebrutinib | 1434048-34-6 | GDC-0853 is a potent and orally BTK inhibitor |
| CSN13839 | GDC-0834 S-enantiomer | 1133432-50-4 | GDC-0834 S-enantiomer is the S-enantiomer of GDC-0834 |
| CSN17489 | GDC-0834 Racemate | 1133432-46-8 | GDC-0834 racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively. |
| CSN17490 | GDC-0834 | 1133432-49-1 | GDC-0834 is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively. |
| CSN17176 | CNX-774 | 1202759-32-7 | CNX-774 is a potent and selective of Btk with IC50 1 nM |
| CSN18870 | CHMFL-BTK-01 | 2095280-64-9 | CHMFL-BTK-01 is an irreversible BTK inhibitor targeting Cys481 residue while completely abolishing BMX JAK3 and EGFRs activity |
| CSN13815 | CGI-1746 | 910232-84-7 | CGI-1746 is a Brutons tyrosine kinase (Btk) inhibitor. |
| CSN22295 | BTK PROTAC 9 | N/A | BTK PROTAC 9 is a potent PROTAC for BTK with DC50 of 59 nM in cultured Ramos cells requires simultaneous engagement of BTK and CRBN to effectively degrade BTK TEC a closely related protein to BTK that potently binds BTK PROTAC 9 is also degraded |
| CSN22294 | BTK PROTAC 10 | N/A | BTK PROTAC 10 is a potent PROTAC for BTK with DC50 of 11 nM in cultured Ramos cells can successfully delivered to tissues and can specifically degrade BTK in vivo in a dose-dependent and tissue-biased manner by sc administration |
| CSN25627 | 2-(3-(4-Amino-6-((1-methyl-1H-pyrazol-4-yl)amino)-1,3,5-triazin-2-yl)-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one | 1646608-10-7 | BTK inhibitor 4b is a highly selective BTK inhibitor with significant efficacy in models in vivo and good ADME and safety profiles. |
| CSN13705 | IBT6A | 1022150-12-4 | Btk inhibitor 1 R-enantiomer is a Btk kinase inhibitor |
| CSN17926 | IBT6A hydrochloride | 1553977-42-6 | Btk inhibitor 1 R-enantiomer HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. |
| CSN17811 | (Rac)-IBT6A | 1412418-47-3 | Btk inhibitor 1 is a pyrazolo34-dpyrimidine derivative as a Btk kinase inhibitor |
| CSN19157 | 3-(4-Phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride | 1807619-60-8 | Btk inhibitor 1 HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. |
| CSN24501 | BTK IN-1 | 1270014-40-8 | BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM. |
| CSN24257 | Branebrutinib | 1912445-55-6 | BMS-986195 is a potent, covalent, irreversible BTK inhibitor with IC50 value of 0.1nM. |
| CSN20297 | BMS-986142 | 1643368-58-4 | BMS-986142 is a potent, selective, reversible BTK inhibitor. BMS-986142 shows BTK IC50 0.5nM and human WB IC50 90 nM. |
| CSN19767 | BMS-935177 | 1231889-53-4 | BMS-935177 is a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. should provide useful clinical efficacy in autoimmune diseases. |
| CSN20168 | (±)-Zanubrutinib | 1633350-06-7 | BGB-3111 is a potent selective and orally available Brutons tyrosine kinase Btk inhibitor |
| CSN16215 | Spebrutinib | 1202757-89-8 | AVL-292 is a covalent and highly selective inhibitor of Btk with IC50 of 0.5 nM, exhibiting 1400-fold selectivity over the other kinases assayed. |
| CSN17749 | Spebrutinib besylate | 1360053-81-1 | AVL-292 benzenesulfonate is a potent inhibitor of Btk kinase activity (IC50 0.5 nM, KinactKi7.69104 M-1s-1s) in biochemical assays. |
| CSN26602 | XMU-MP-3 | 2031152-08-4 | ATP, respectively. XMU-MP-3 also induces apoptosis[1]. |
| CSN21093 | ARQ 531 | 2095393-15-8 | ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity. |
| CSN16252 | Acalabrutinib | 1420477-60-6 | Acalabrutinib is a second-generation selective and irreversible inhibitor of BTK Brutons tyrosine kinase with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay Acalabrutinib has improved pharmacologic features including favorable plasma exposure rapid oral absorption a short half-life and the absence of irreversible targeting to alternative kinases |
| CSN22895 | Terreic acid | 121-40-4 | (-)-Terreic Acid is a selective inhibitor of Bruton's tyrosine kinase (BTK). |
| CSN28534 | DD 03-171 | 2366132-45-6 | Potent and selective BTK Degrader (PROTAC®) |
| CSN51412 | BCPyr | 2669844-82-8 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
